title: The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma.
abstract: Experimental studies have suggested that nicotinamide and its analogs may inhibit the growth of murine tumours. We have now investigated this using a C3H mouse mammary carcinoma implanted into the right rear foot of female CDF1 mice. From days 1 to 30 after implantation mice were intraperitoneally (i.p.) injected with either 100, 200, 500 or 1,000 mg/kg nicotinamide. The tumour volume (+/- 1 S.E.) after 30 days in saline-treated mice had reached 1540 mm3 (+/- 260). No change in tumour growth was seen at that time with daily doses of up to 500 mg/kg nicotinamide, but at 1,000 mg/kg tumour volume was reduced to 904 mm3 (+/- 233). However, this large dose of nicotinamide was also toxic to the mice with some 16% of animals dying during the 30-day treatment period. A similar growth inhibition was seen with daily i.p. injections of 5 mg/kg fumagillin (tumour volume at 30 days = 821 +/- 191 mm3), a known inhibitor of angiogenesis, but whether this mechanism also explains the nicotinamide effect is not clear.
authors.affiliation: Department of Experimental Clinical Oncology, Aarhus, Denmark.
authors.forename: M R
authors.initials: MR
authors.lastname: Horsman
authors.forename: A A
authors.initials: AA
authors.lastname: Khalil
authors.forename: D J
authors.initials: DJ
authors.lastname: Chaplin
authors.forename: J
authors.initials: J
authors.lastname: Overgaard
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D002455:Cell Division / Q000187:drug effects; D003510:Cyclohexanes; D004305:Dose-Response Relationship, Drug; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology*; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D009536:Niacinamide / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D011336:Probability; D012717:Sesquiterpenes
chemical_list: D000970:Antineoplastic Agents; D003510:Cyclohexanes; D005231:Fatty Acids, Unsaturated; D012717:Sesquiterpenes; D009536:Niacinamide; C026211:fumagillin